European Medical Journal2d
Osimertinib’s Role in Detecting Residual Lung Cancer
Explore how adjuvant osimertinib aids in detecting molecular residual disease in resected EGFR-mutated NSCLC, offering ...
ascopubs.org17d
Accelerating Myeloma Drug Development: Will Minimal Residual Disease Replace Progression-Free Survival as an Intermediate Surrogate End Point?
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in ...
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ ...
Morningstar11d
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma
which included language recommending ctDNA testing for MRD assessment for patients with PET-positive DLBCL at end of first-line treatment. DLBCL is the most common form of non-Hodgkin lymphoma ...
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...
Natera: Solid Execution, Pricey Stock
Discover why analysts remain bullish on Natera, Inc., a leader in oncology testing, despite GAAP losses and insider stock ...
Making food from our organic waste may not be as good an idea as first thought
Waste-to-nutrition technologies aim to transform residual organic waste (such as forestry and agricultural residues, manure, ...
Mirage News1d
Residual Cancer Threat: Clear Scans May Mislead
SABR is a well-established therapy in both the curative and metastatic setting, however, its ablative potential may not be as high as suggested by ...